December 7, 2023 – In August 2023, the pCPA engaged with clinicians, patient groups and industry to present and hear feedback on a set of principles and conditions for a pCPA Temporary Access Process (pTAP).
pTAP will inform negotiations for drug products that follow time-limited reimbursement recommendations (TLRs) from the Canadian Agency for Drugs and Technologies in Health (CADTH). The shared goal is to improve accessibility to promising new treatments. In addition to hearing feedback from these stakeholders during online sessions, we received written submissions from 31 parties representing a multitude of members across Canada. Overall, our stakeholders indicated support for pTAP, but also expressed concerns about some of the proposed principles and conditions.
Visit our pTAP page to learn more about what we heard from stakeholders.